Compare ACU & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACU | KPTI |
|---|---|---|
| Founded | 1867 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.0M | 148.0M |
| IPO Year | N/A | 2013 |
| Metric | ACU | KPTI |
|---|---|---|
| Price | $43.34 | $6.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $22.17 |
| AVG Volume (30 Days) | 8.2K | ★ 413.6K |
| Earning Date | 02-27-2026 | 02-18-2026 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $194,960,991.00 | $142,530,000.00 |
| Revenue This Year | $2.19 | $3.82 |
| Revenue Next Year | $4.55 | N/A |
| P/E Ratio | $17.83 | ★ N/A |
| Revenue Growth | ★ 2.35 | N/A |
| 52 Week Low | $35.20 | $3.51 |
| 52 Week High | $45.25 | $10.80 |
| Indicator | ACU | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 74.24 | 39.97 |
| Support Level | $42.50 | $7.05 |
| Resistance Level | $43.94 | $8.95 |
| Average True Range (ATR) | 1.14 | 0.62 |
| MACD | 0.21 | -0.18 |
| Stochastic Oscillator | 100.00 | 1.85 |
Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.